Literature DB >> 2983548

Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome.

D E Stover, D A White, P A Romano, R A Gellene, W A Robeson.   

Abstract

Over a four-year period, 130 patients with the acquired immune deficiency syndrome were studied to assess the incidence and spectrum of pulmonary disease associated with this illness. In 61 patients (47 percent), respiratory abnormalities were either present on admission or later developed. Multiple pathologic processes were present simultaneously in 24 patients and serial pulmonary problems developed in seven patients. Infection was the most common cause of pulmonary parenchymal disease and was due to Pneumocystis carinii (35 patients), cytomegalovirus (21 patients), Mycobacterium avium-intracellulare (13 patients), and bacteria (four patients). Noninfectious causes of parenchymal lung diseases were also frequently seen and included Kaposi's sarcoma (eight patients), non-specific pneumonitis (seven patients), and adult respiratory distress syndrome (four patients). Significant pleural disease was present in six cases and was usually related to Kaposi's sarcoma. A bronchospastic disorder developed in four patients. Pulmonary function tests, in particular the diffusing capacity and the difference between rest and exercise alveolar-arterial oxygen tension, were helpful in screening for pulmonary diseases. Patterns of clinical features and radiographic abnormalities were recognized and suggested specific diagnoses. Overall mortality from respiratory causes identified during the study was 41 percent, but varied markedly with the etiologic agent. Respiratory failure, however, carried a 100 percent mortality despite the underlying cause.

Entities:  

Mesh:

Year:  1985        PMID: 2983548     DOI: 10.1016/0002-9343(85)90334-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  37 in total

1.  Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS.

Authors:  M J Gill; R Read
Journal:  Can J Infect Dis       Date:  1991

Review 2.  AIDS and the lung: update 1992. 2. Recent developments in the management of the pulmonary complications of HIV disease.

Authors:  D M Mitchell; R F Miller
Journal:  Thorax       Date:  1992-05       Impact factor: 9.139

3.  Clinical and bronchoscopic diagnosis of suspected pneumonia related to AIDS.

Authors:  A L Pozniak; K T Tung; C R Swinburn; S Tovey; S J Semple; N M Johnson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-09-27

Review 4.  Agents of newly recognized or infrequently encountered mycobacterial diseases.

Authors:  L G Wayne; H A Sramek
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

Review 5.  Pulmonary complications of intravenous drug misuse. 2. Infective and HIV related complications.

Authors:  C R Hind
Journal:  Thorax       Date:  1990-12       Impact factor: 9.139

Review 6.  AIDS and the lung. 4-- Non-invasive investigation of pulmonary disease in patients positive for the human immunodeficiency virus.

Authors:  A B Millar; D M Mitchell
Journal:  Thorax       Date:  1990-01       Impact factor: 9.139

7.  Lung function abnormalities in patients infected with the human immunodeficiency virus with and without overt pneumonitis.

Authors:  R J Shaw; C Roussak; S M Forster; J R Harris; A J Pinching; D M Mitchell
Journal:  Thorax       Date:  1988-06       Impact factor: 9.139

8.  Health insurance and utilization in Pneumocystis carinii pneumonia.

Authors:  S Loue; D J Slymen; H Morgenstern; C Whalen
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

9.  Human cytomegalovirus-induced immunosuppression. Relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E2 in human monocytes.

Authors:  M A Nokta; M I Hassan; K Loesch; R B Pollard
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

Review 10.  Optimal management strategies for HIV-infected patients who present with cough or dyspnea: a cost-effective analysis.

Authors:  K A Freedberg; A N Tosteson; D J Cotton; L Goldman
Journal:  J Gen Intern Med       Date:  1992 May-Jun       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.